제품 수집제품 세부정보
Materials Provided
IDComponentsSizeEP130-C01High-bind Plate1 plateEP130-C02Human PD-110 μgEP130-C03Biotinylated Human PD-L120 μgEP130-C04Anti-PD-1 Neutralizing Antibody20 μgEP130-C05Streptavidin-HRP10 μgEP130-C06Coating Buffer12 mLEP130-C0710xWashing Buffer50 mLEP130-C08Blocking Buffer50 mLEP130-C09Substrate Solution24 mLEP130-C10Stop Solution7 mLProduct Overview
PD-1 : PD-L1 [Biotinylated] Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human PD-1 binding to human PD-L1. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human PD-1 binding to human PD-L1.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
고객님도 확인한 상품
데이터 표시
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF PD-1: PD-L1 [BIOTINYLATED] BINDING BY ANTI-PD-1 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-PD-1 Neutralizing antibody (Catalog # EP130-C04) (1:1 serial dilution, from 5μg/mL to 0.02μg/mL) was added into PD-1: Biotinylated PD-L1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
사용자 리뷰 댓글 남기기
프론티어 진행
의약품 개발 진행- 영어 이름：
Programmed cell death protein 1
- 카테고리：
- 상장 의약품 수：
22 상세
- 임상 의약품 수：
193 상세
- 최고 개발 단계：
Approved
연락하기
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
신약 후보물질 라이선싱
